Department of Molecular Neuroscience, World Premier International, Immunology Frontier Research Center, Osaka University, Suita-shi, Osaka, Japan.
Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita-shi, Osaka, Japan.
Glia. 2019 Sep;67(9):1694-1704. doi: 10.1002/glia.23640. Epub 2019 May 20.
Secondary progressive multiple sclerosis (SPMS) is an autoimmune disease of the central nervous system (CNS) characterized by progressive motor dysfunction, sensory deficits, and visual problems. The pathological mechanism of SPMS remains poorly understood. In this study, we investigated the role of microglia, immune cells in the CNS, in a secondary progressive form of experimental autoimmune encephalomyelitis (EAE), the mouse model of SPMS. We induced EAE in nonobese diabetic mice and treated the EAE mice with PLX3397, an antagonist of colony stimulating factor-1 receptor, during secondary progression in order to deplete microglia. The results showed that PLX3397 treatment significantly exacerbated secondary progression of EAE and increased mortality rates. Additionally, histological analysis showed that PLX3397 treatment significantly promoted inflammation, demyelination, and axonal degeneration. Moreover, the number of CD4 T cells in the spinal cord of EAE mice was expanded due to PLX3397-mediated proliferation. These results suggest that microglia suppressed secondary progression of EAE by inhibiting the proliferation of CD4 T cells in the CNS.
继发进展型多发性硬化症(SPMS)是一种中枢神经系统(CNS)自身免疫性疾病,其特征为进行性运动功能障碍、感觉缺失和视觉问题。SPMS 的病理机制仍不清楚。在这项研究中,我们研究了小胶质细胞(CNS 中的免疫细胞)在实验性自身免疫性脑脊髓炎(EAE)的继发性进展形式(SPMS 的小鼠模型)中的作用。我们在非肥胖型糖尿病(NOD)小鼠中诱导 EAE,并在继发性进展期间用 PLX3397(集落刺激因子-1 受体拮抗剂)治疗 EAE 小鼠以耗竭小胶质细胞。结果表明,PLX3397 治疗显著加重 EAE 的继发性进展并增加死亡率。此外,组织学分析表明,PLX3397 治疗显著促进炎症、脱髓鞘和轴突变性。此外,由于 PLX3397 介导的增殖,EAE 小鼠脊髓中的 CD4 T 细胞数量增加。这些结果表明,小胶质细胞通过抑制 CNS 中 CD4 T 细胞的增殖来抑制 EAE 的继发性进展。